Why the study?
Does dexrazoxane prevent myocardial dysfunction and allow for successful induction chemotherapy in patients with acute myelogenous leukemia and ischemic heart disease?
Does dexrazoxane prevent myocardial dysfunction and allow for successful induction chemotherapy in patients with acute myelogenous leukemia and ischemic heart disease?
Dexrazoxane may be a useful cardioprotectant to allow safe administration of anthracycline or anthracenedione induction chemotherapy in AML patients with pre-existing ischemic heart disease.
Answers are grounded in this paper and cite their sources.
May support dexrazoxane cardioprotection in AML induction; hypothesis-generating case report requiring prospective trials before practice change.
Treatment of acute myelogenous leukemia is challenging in the setting of ischemic heart disease because anthracycline and anthracenedione drugs used in induction chemotherapy may potentiate myocardial dysfunction. We have managed two patients with coincident acute myelogenous leukemia and ischemic heart disease with the cardioprotectant drug dexrazoxane (ICRF-187), administered before each dose of mitoxantrone or idarubicin. Both patients tolerated their induction chemotherapy, developed marrow hypoplasia from chemotherapy, and achieved clinical remission. Dexrazoxane may have a role as a cardioprotectant in the treatment of select patients with acute myelogenous leukemia.
No takes yet. Share an insight, caveat, or question.
Woodlock et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: